Drugs / Equine COVID-19 Antiserum
Equine COVID-19 Antiserum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04834908 | Jul 2021 → May 2022 | COVID-19 | Bharat Serums and Vaccines Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Equine COVID-19 Antiserum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04834908 ↗ |
| Modality | Protein / enzyme biologic | “Equine COVID-19 antiserum is a polyclonal antibody” NCT04834908 ↗ |
| Route | Intravenous | “It is administered as a single dose intravenously” NCT04834908 ↗ |